HK Grey Market | Metis TechBio Soars 191%; Impact Therapeutics Jumps 41%
View all comments(0)
Metis TechBio, one of the "Top Three AI Drug Discovery" companies in Mainland China, soared 191% in Hong Kong’s grey market trading.
Founded in 2020, Metis TechBio focuses on the delivery and application of payloads across a range of biological systems, using artificial intelligence-powered nanotechnology to advance healthcare solutions.

Chinese cancer-drug developer Impact Therapeutics jumped 41% in Hong Kong’s grey market trading.
Founded in 2009, Impact Therapeutics is a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End

SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?

PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today

Tradingkey








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.